Spinal Cord Injury Tai Chi Practice

By: Jeffery Morris

Go here to read the rest:
Spinal Cord Injury Tai Chi Practice - Video

Recommendation and review posted by sam

Stem Cell Therapy Treatment for Spino Muscular Atrophy by Dr Alok Sharma, Mumbai, India
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Spino Muscular Atrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Stamina has improved. 2. Fatigue is...

By: Neurogen Brain and Spine Institute

Originally posted here:
Stem Cell Therapy Treatment for Spino Muscular Atrophy by Dr Alok Sharma, Mumbai, India - Video

Recommendation and review posted by simmons

Strides in Heart Care: Personalized Medicine - PREDICT
Vanderbilt Heart doctors, nurses and patients explain how patients and families can benefit from the next wave of technology and treatment options. To learn ...

By: Vanderbilt Health

Link:
Strides in Heart Care: Personalized Medicine - PREDICT - Video

Recommendation and review posted by sam

Can you Get Disability Benefits for a Spinal Cord Injury Claim?
In this Video Marc Whitehead, a Board Certified Disability Attorney, explains whether or not you are able to get disability benefits for a spinal cord injury.

By: Marc Whitehead

Continued here:
Can you Get Disability Benefits for a Spinal Cord Injury Claim? - Video

Recommendation and review posted by sam

Nurturing the science behind regenerative medicine
Speakers Dr Paul Fairchild, Oxford Stem Cell Institute Further Information October 2008: Showcase: Oxford Stem Cell Institute - Dr Paul Fairchild Oxford Mart...

By: 21school

Continue reading here:
Nurturing the science behind regenerative medicine - Video

Recommendation and review posted by sam

ONE Musicfest 2013, Goodie Mob "Cell Therapy"
ONE Musicfest 2013 (www.onemusicfest.com), snippet of Goodie Mob performing "Cell Therapy."

By: koolnessnofoolness

Read the original post:
ONE Musicfest 2013, Goodie Mob "Cell Therapy" - Video

Recommendation and review posted by Bethany Smith

SYDNEYand AUCKLAND, New Zealand, Sept. 19, 2013 /PRNewswire/ --Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) a potential treatment for Parkinson's disease.

The pioneering brain surgery was conducted at Auckland City Hospital and the patient has recovered well so far. An MRI scan taken the day after the surgery indicated that the NTCELL capsules have been implanted at their intended target. The patient and family have requested privacy and no contact with the media.

The Phase I clinical trial is an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinson's disease for at least four years. The first patient will now be monitored for two months to confirm no serious adverse safety events. At that time, the independent data safety monitoring board (DSMB) will consider the safety data and advise if the implants for the remaining three patients can proceed.

The trial Principal Investigator is Dr Barry Snow (MBChB, FRACP, FRCPC), an internationally recognised clinician and researcher in Parkinson's disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. "The team are pleased with how well the patient tolerated the procedure itself," says Dr Snow. "The surgery is relatively straightforward in neurosurgery terms, and we have taken full advantage of well-established techniques, which lowers the clinical risk. The patient will now be monitored closely by the team over the next two months."

Dr Andrea Grant, CEO and Managing Director of LCT says: "This is a significant milestone and a world first. It has taken a great deal of hard work, clinical and scientific endeavour to get to this and so of course we are excited. The purpose of this "first-in-man" study is to demonstrate the treatment is safe. Provided this trial is succesful, future trials will further assess the extent of clinical benefit that patients might gain."

In the clinical trial, NTCELL is injected under guidance by neuroimaging into the affected area of the human brain where substantial death of neurons and other cells has occurred. The cell therapy is comprised of choroid plexus cells, which are naturally occurring 'support' cells for the brain. LCT's propriety technology IMMUPEL(R) coats the implanted cells to protect them from attack by the patient's immune system.

The scientific basis for the Phase I clinical trial in humans was established from the published preclinical trial of NTCELL(R) in a non-human primate model of Parkinson's disease. The preclinical results indicate that NTCELL can protect and regenerate brain tissue that would otherwise be lost, potentially delaying or even preventing the effects of Parkinson's disease.

"Unlike current therapy options for Parkinson's disease, NTCELL may be neuroprotective and offers people living with the disease the hope of being able to halt disease progression and restore quality of life," says Dr Grant.

LCT and Otsuka Pharmaceutical Factory (OPF) are co-developing NTCELL as a treatment for Parkinson's disease. Under the agreement, LCT has already received an A$3m cash payment and OPF is funding all of the research and development costs associated with the Phase I clinical trial, estimated at AU$2.1m. In addition, LCT will receive a second cash payment of AU$2m provided the DSMB authorise the remaining three implants later in the year.

For further information: http://www.lctglobal.com

Read more:
'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease

Recommendation and review posted by Bethany Smith

Public release date: 19-Sep-2013 [ | E-mail | Share ]

Contact: Sarah Smith sas2072@med.cornell.edu 646-317-7401 Weill Cornell Medical College

NEW YORK (September 19, 2013) -- Researchers at Weill Cornell Medical College have discovered why a tiny alteration in a brain gene, found in 20 percent of the population, contributes to the risk for anxiety, depression and memory loss.

Their discovery, reported in Nature Communications, describes new functions for the alteration, a single nucleotide polymorphism (SNP) in the brain-derived neurotrophic factor (BDNF) gene. This gene is a powerful regulator of the growth and function of neurons, and the establishment of brain circuitry. The common alteration occurs when a single "letter" of BDNF's genetic code is "misspelled."

The team of investigators, led by Dr. Clay Bracken, associate research professor of biochemistry and director of the nuclear magnetic resonance facility, Dr. Barbara Hempstead, professor of medicine, and Dr. Francis Lee, professor of psychiatry, all at Weill Cornell Medical College, discovered that the alteration appears to induce shrinkage of neurons from the hippocampus (an important region for memory and emotion), reducing connectivity between brain cells.

The discovery upends the prevailing theory about how the BDNF SNP alters the function of the brain, says Dr. Agustin Anastasia, first author of the article and a postdoctoral fellow in the Hempstead lab. "Research on BDNF is very active worldwide, and the conventional wisdom of the field was that the SNP reduced the amount of BDNF that was secreted. Therefore, many investigators were trying to increase production of the protein -- but this effort was only moderately successful."

"While the SNP does decrease the amount of BDNF in neurons, it generates a protein, the Met66 prodomain, that is different from the Val66 prodomain that is generated by the 80 percent of the human population that does not carry the SNP," Dr. Hempstead says. "The Met66 prodomain binds to specific proteins on the surface of neurons, to induce the pruning or shrinkage of these neurons."

The findings offer mechanistic insight into why some depression and anxiety runs in families, Dr. Lee says. "There can be a heritable component to these diseases and it makes sense that a common variant in a gene could be involved," he says. "Just like hypertension contributes to the risk for heart disease, the BDNF alteration increases the risk of depression, anxiety and memory disorders -- but is not the sole reason why they occur."

Still, targeted treatment for the genetic alteration could provide the first true benefit for affected patients, who often don't respond to traditional treatments, Dr. Lee says. "We can easily test patients for the mutation by using a simple blood test," he says. "We just need novel targeted treatments that alter the effects of the BDNF SNP-- and now we have a good lead on what that therapy should do."

The other half of the story

Read more here:
Researchers tease apart workings of a common gene

Recommendation and review posted by Bethany Smith

London, Sept 20 : A team of researchers led by King's College London has for the first time identified a new gene which may have the ability to prevent HIV, the virus that causes AIDS, from spreading after it enters the body.

The study is the first to identify a role for the human MX2 gene in inhibiting HIV.

Researchers say this gene could be a new target for effective, less toxic treatments where the body's own natural defence system is mobilised against the virus.

The work was funded by the Medical Research Council and the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The study was also supported by the Wellcome Trust and European Commission.

Scientists carried out experiments on human cells in the lab, introducing the virus to two different cell lines and observing the effects. In one cell line the MX2 gene was expressed or 'switched on', and in the other it was not, or 'silenced'.

They saw that in the cells where MX2 was silenced, the virus replicated and spread. In the cells where the MX2 gene was expressed, the virus was not able to replicate and new viruses were not produced.

The work was led by Dr Caroline Goujon and Professor Mike Malim at theDepartment of Infectious Diseases, King's College London.

Professor Malim said: "This is an extremely exciting finding which advances our understanding of how HIV virus interacts with the immune system and opens up opportunities to develop new therapies to treat the disease. Until now we knew very little about the MX2 gene, but now we recognise both its potent anti-viral function and a key point of vulnerability in the life cycle of HIV.

"Developing drugs to stimulate the body's natural inhibitors is a very important approach because you are triggering a natural process and therefore won't have the problem of drug resistance. There are two possible routes - it may be possible to develop either a molecule that mimics the role of MX2 or a drug which activates the gene's natural capabilities."

"Although people with HIV are living longer, healthier lives with the virus thanks to current effective treatments, they can often be toxic for the body and drug resistance can become an issue with long-term use. It is important to continue to find new ways of mobilising the body's natural defence systems and this gene appears to be a key player in establishing viral control in people with HIV."

View original post here:
Gene discovery may lead to new HIV treatments

Recommendation and review posted by Bethany Smith

The Ultimate Anti-Aging Tool - Wave Genetics by Dr. Peter Garyaev
http://wavegenetics.org/en - Wave Genetics by Dr. Peter Garyaev. Theory of wave genetics is the first scientific tool in the whole history of mankind that ca...

By: wavegenetics

Read the rest here:
The Ultimate Anti-Aging Tool - Wave Genetics by Dr. Peter Garyaev - Video

Recommendation and review posted by Bethany Smith

Diagnostic US Harms DNA. Dr. Peter Garyaev
http://wavegenetics.org/en Professor of Biology Peter Garyaev is the founding father of wave genetics — a truly revolutionary theory in modern science that c...

By: wavegenetics

Read more from the original source:
Diagnostic US Harms DNA. Dr. Peter Garyaev - Video

Recommendation and review posted by Bethany Smith

Boring Genetics class.

By: Lyla Misiam

See the article here:
Boring Genetics class. - Video

Recommendation and review posted by Bethany Smith

Barbara Franke - How to make sense of genetics for psychiatric disorders? (2013)
Keynote lecture at Neuroinformatics 2013 in Stockholm, Sweden Barbara Franke, Radboud University Medical Centre in Nijmegen, Nijmegen, The Netherlands.

By: INCForg

Originally posted here:
Barbara Franke - How to make sense of genetics for psychiatric disorders? (2013) - Video

Recommendation and review posted by Bethany Smith

Charleroi-Durable.be : Delphi Genetics
Activités High Tech dans un bâtiment passif ! Le développement durable selon Delphi Genetics , c #39;est ... - Un bâtiment passif, compatible avec une activité industrielle - Une valeur ajoutée,...

By: IgretecAnimEco

Read the rest here:
Charleroi-Durable.be : Delphi Genetics - Video

Recommendation and review posted by Bethany Smith

New Alex Collier: Alien Hybrid Genetics
Alex Collier Contactee abductee Alien reptilian agenda disclosed genetic influence hybrid racial interracial andromedan andromeda nibiru planet x anunnaki gr...

By: Disclosure TV

Read more:
New Alex Collier: Alien Hybrid Genetics - Video

Recommendation and review posted by Bethany Smith

Association for Molecular Pathology vs. Myriad Genetics - Arti Rai
September 9, 2013 - National Advisory Council for Human Genome More: http://www.genome.gov/27554864.

By: GenomeTV

Read more from the original source:
Association for Molecular Pathology vs. Myriad Genetics - Arti Rai - Video

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Panna Sharma, president and CEO of Cancer Genetics, Inc. (CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, provides insight and commentary on its expanding relationship with Roche Servicios, S.A., an affiliate of Swiss drug maker Roche, in this pre-recorded video interview. Click here to view:

Some key highlights covered in the interview with Mr. Sharma include:

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see http://www.cancergenetics.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

View original post here:
CEO of Cancer Genetics, Inc. Provides Commentary on the Company's Expanded Relationship With Roche Servicios S.A.

Recommendation and review posted by Bethany Smith

Public release date: 19-Sep-2013 [ | E-mail | Share ]

Contact: Kathy Ridgely Beal kbeal@acmg.net 301-238-4582 American College of Medical Genetics

September 19, 2013 Bethesda, MD Genetic tests can now tell us whether we are at increased risk of various cancers, heart or kidney disease, asthma and a number of other conditions.

Other genetic tests can tell whether you will respond to certain medicines or be harmed by side effects linked to your genetic code. But harnessing that information to benefit individual patients and prevent illnesses in others will require that doctors have access to genomic information for each patient. As health records are converted to digital form, the most likely place to store and retrieve genomic information will be Electronic Health Records (EHR). But when and how that happens will depend on having good models to build upon.

Now, in the first collection of its kind, the October 2013 issue of Genetics in Medicine, the official peer-reviewed journal of the American College of Medical Genetics and Genomics, provides a series of research articles detailing challenges and solutions for integrating genomic data into EHR. The issue features the insights of research teams actively engaged in integrating genomic medicine into clinical care. Most of the contributions derive from the experiences of individual sites that comprise the Electronic Medical Records and Genomics (eMERGE) Network, a national consortium funded by the National Institutes of Health, but additional perspective is provided by a commercial EHR vendor and by the Clinical Sequencing Exploratory Research (CSER) consortium, a cooperative group exploring applications of genomic sequencing.

"Our hope is that this issue of Genetics in Medicine will serve as a 'how to' and 'what to think about' for any group tasked with launching a genomics program and integrating this data into the EHR at the point of care," said Joseph Kannry, MD, a board-certified internist and Lead Technical Informaticist of the Epic Clinical Transformation Group, Mount Sinai Medical Center, New York, NY. "This issue should serve as a reference point for many years to come."

Dr. Kannry and co-editor Marc Williams, MD FACMG, director of the Genomic Medicine Institute, Geisinger Health System, Danville, Pa., steered the effort to organize contributions and together wrote the lead editorial. In it they state that, "Successfully integrating genomics into clinical care requires a vision, a strategy that will achieve the vision, and an actionable implementation plan." The case studies provided in this special issue outline the following challenges and potential solutions:

How can genomics be meaningfully incorporated into routine healthcare? [Hartzler et al. doi: GIM.2013.127] describe how a broad range of parties, including institutional leadership, physicians, information technology staff, and patients must be included in the conversation if genomic medicine is to be successful. The article describes different ways to ensure support systems are in place when launching a genomic medicine project.

How will genomic data be stored, processed, updated and retrieved? [citation: Kho et al. doi: GIM.2013.131] examine data currently captured in EHR systems and compare that to genomic data. They look forward to the need for long-term storage and retrieval and how data can be accessed and compared across time and in changing clinical circumstances.

Likewise, [Chute et al. doi: gim.2013.121] discuss the opportunities for large data sets of genomic information to help detect new genomic risk factors and clinically important information not possible until recently. They identify gaps in standards for coding and transmission of data and propose solutions.

View original post here:
Genetics in Medicine publishes special issue dedicated to genomics in electronic health records

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwired - Sep 19, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, will display its ForeCYTE Breast Health Test at the Pri-Med East 2013 Conference & Exhibition from September 19 through September 22, 2013, in Boston, MA. Atossa's exhibit will be located in Booth 903 at the Boston Convention & Exhibition Center.

Chris Destro, Vice President, Sales and Marketing for Atossa, stated, "The Pri-Med East show is a strategic venue and opportunity as we continue to market the ForeCYTE Breast Health Test.We look forward to having representatives demonstrate our collection device and to expand on the clinical value of our test to the primary care providers attending the show."

The ForeCYTE Breast Health Test, developed and marketed by Atossa's subsidiary, The National Reference Laboratory for Breast Health, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses Atossa's hand-held, FDA Class II medical device that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here: https://vimeo.com/62365818.

About the Pri-Med 2013 Conference & Exhibition

The Pri-Med Conference & Exhibition offers low-cost continuing medical education in a flexible format. The CME conference schedule is designed to maximize participants' time out of the office, providing clinical updates on the disease states and patients treated daily.

Topics of interest for this conference include:

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office.The test specimens are then analyzed at Atossa's laboratory, The National Reference Laboratory for Breast Health, Inc. (NRLBH), which can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes. For more information, please visit getforecyte.com.

Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.

The rest is here:
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the Pri-Med East 2013 Conference & Exhibition

Recommendation and review posted by Bethany Smith

Spinal Cord Injury Mashup
BCCC NURS3 2013 Video Mash-UP ON SCI #39;s.

By: jmorales1539

Follow this link:
Spinal Cord Injury Mashup - Video

Recommendation and review posted by sam

Hitguj Stem Cell Therapy
For more info log on to http://www.24taas.com Like us on https://www.facebook.com/Zee24Taas Follow us on https://twitter.com/zee24taasnews.

By: Zee24Taas

View post:
Hitguj Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Basser Research CenterPoster shown in synagogues

Many Jewish women attending their synagogues high holiday services this month may have seen posters plastered on bulletin boards or near the entrance doors warning them that they may be at increased risk of breast and ovarian cancer.

Individuals of Ashkenazi Jewish ancestry have a 1 in 40 chance of carrying a BRCA gene mutation, reads the poster. This is at least a ten times greater probability than that of the general population. The advice: Talk to experts at Basser Research Center for BRCA at Penn Medicines Abramson Cancer Center to understand your risk. The implied message: You may have a BRCA mutation and could be a good candidate for genetic testing.

Temple Beth Am in Framingham and Temple Ohabei Shalom in Brookline have these posters up on their walls, as do 1,500 other synagogues across the country.

Dr. Susan Domchek, an oncologist, genetic researcher and executive director of the Basser Research Center, told me that the poster campaigns mission is to simply increase awareness and get women to seek more information on whether they would qualify for genetic testing.

Many are already well aware of the gene mutation, especially after actress Angelina Jolie revealed that she was a BRCA-mutation carrier and had a prophylactic mastectomy to reduce her elevated risk of breast cancer.

The trouble I have with this campaign is that it leads Jewish women to believe that they likely need BRCA testing. Most dont, and insurance will cover the $3,000 cost of the screening only if they have at least one first-degree relativemother, sister, daughterdiagnosed with breast or ovarian cancer.

Domchek said the poster couldnt include all these nuances but directs women to a website where more information can be found. Women need to click on yet another link to find out that they should only seek advice from a genetic counselor if they are of Eastern European Jewish descent and have a close family history of breast or ovarian cancer.

I think a single extra sentence on this poster may have gone a long way towards providing women with the full information so they dont need to be scared unnecessarily into thinking that they need an expensive genetic test simply because of their ancestry.

See more here:
Poster campaign urges Jewish women to get cancer gene screening

Recommendation and review posted by Bethany Smith

Public release date: 18-Sep-2013 [ | E-mail | Share ]

Contact: Katya Nasim katya.nasim@kcl.ac.uk 44-020-784-83840 King's College London

A team of researchers led by King's College London has for the first time identified a new gene which may have the ability to prevent HIV, the virus that causes AIDS, from spreading after it enters the body.

Published in Nature today, the study is the first to identify a role for the human MX2 gene in inhibiting HIV. Researchers say this gene could be a new target for effective, less toxic treatments where the body's own natural defence system is mobilised against the virus.

The work was funded by the Medical Research Council and the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The study was also supported by the Wellcome Trust and European Commission.

Scientists carried out experiments on human cells in the lab, introducing the virus to two different cell lines and observing the effects. In one cell line the MX2 gene was expressed or 'switched on', and in the other it was not, or 'silenced'. They saw that in the cells where MX2 was silenced, the virus replicated and spread. In the cells where the MX2 gene was expressed, the virus was not able to replicate and new viruses were not produced.

The work was led by Dr Caroline Goujon and Professor Mike Malim at the Department of Infectious Diseases, King's College London. Professor Malim said: "This is an extremely exciting finding which advances our understanding of how HIV virus interacts with the immune system and opens up opportunities to develop new therapies to treat the disease. Until now we knew very little about the MX2 gene, but now we recognise both its potent anti-viral function and a key point of vulnerability in the life cycle of HIV.

"Developing drugs to stimulate the body's natural inhibitors is a very important approach because you are triggering a natural process and therefore won't have the problem of drug resistance. There are two possible routes it may be possible to develop either a molecule that mimics the role of MX2 or a drug which activates the gene's natural capabilities.

"Although people with HIV are living longer, healthier lives with the virus thanks to current effective treatments, they can often be toxic for the body and drug resistance can become an issue with long-term use.

It is important to continue to find new ways of mobilising the body's natural defence systems and this gene appears to be a key player in establishing viral control in people with HIV."

View post:
Novel gene discovery could lead to new HIV treatments

Recommendation and review posted by Bethany Smith

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo! News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix Beyond the Headline Local Popular Search Keyword News Search

Continue reading here:
Gene discovery could lead to new types of HIV treatments

Recommendation and review posted by Bethany Smith

Public release date: 18-Sep-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, September 18, 2013 Journal of Men's Health, a peer-reviewed journal now published online with Open Access options and in print by Mary Ann Liebert, Inc., publishers, reflects the urgent priority to improve the health of men around the globe. Volume 10, Issue 1 will be published on the new Journal of Men's Health website at http://www.liebertpub.com/jmh in late September 2013. Journal of Men's Health was formerly published by Elsevier.

"With our new publisher, Mary Ann Liebert, Inc., Journal of Men's Health will include an expanded focus on evidence-based and translational research that will advance knowledge in the field of men's health and ensure optimal patient care," says Ridwan Shabsigh, MD, President of the International Society of Men's Health (ISMH); Chairman, Department of Surgery, St. Barnabas Hospital (Bronx, NY); and Professor of Clinical Urology, Cornell University (New York). Journal of Men's Health is the official journal of the International Society of Men's Health, American Society for Men's Health, and Men's Health Society of India. The vision and mission of the Journal is broadly outlined in a far-reaching editorial by Dr. Shabsigh.

Journal of Men's Health provides in-depth coverage of gender-specific diseases and conditions, such as prostate disease and male sexual dysfunction, along with non-gender-specific diseases and conditions with higher prevalence or special impact in men, including cardiovascular disease, metabolic syndrome, chronic obstructive pulmonary disease, cancers of the lung, colon, bladder and liver, and schizophrenia and obsessive compulsive disorder.

"Mary Ann Liebert, Inc. brings a wealth of knowledge, energy, passion, and enthusiasm for gender-specific medicine," says Editor-in-Chief Ajay Nehra, MD, Chair, Department of Urology and Director, Men's Health, Rush University Medical Center (Chicago, IL). "This partnership will help to develop the field of men's health and the Journal will provide an important forum for provocative and cutting-edge articles that address men's health issues across the lifespan."

The Journal publishes original research and review articles on population studies, clinical research, guidelines and best practices, professional training and education, and cultural competence in the delivery of health care from adolescence through the older adult years. Peer-reviewed articles will be augmented by provocative editorials and perspectives on new approaches to the prevention, diagnosis, and treatment of disease that are relevant to all those involved in men's healthclinicians, researchers, educators, and policymakers.

###

About the Journal

Journal of Men's Health is the premier peer-reviewed journal published quarterly in print and online that covers all aspects of men's health across the lifespan. The Journal publishes cutting-edge advances in a wide range of diseases and conditions, including diagnostic procedures, therapeutic management strategies, and innovative clinical research in gender-based biology to ensure optimal patient care. The Journal addresses disparities in health and life expectancy between men and women; increased risk factors such as smoking, alcohol abuse, and obesity; higher prevalence of diseases such as heart disease and cancer; and health care in underserved and minority populations. Journal of Men's Health meets the critical imperative for improving the health of men around the globe and ensuring better patient outcomes. Complete information may be viewed on the Journal of Men's Health website at http://www.liebertpub.com/jmh.

See original here:
Journal of Men's Health now published by Mary Ann Liebert, Inc.

Recommendation and review posted by Bethany Smith